The Drug Repurposing for COVID-19 Clinical Trials Provide Very Effective Therapeutic Combinations: Lessons Learned From Major Clinical Studies
SARS-CoV-2 has spread across the globe in no time. In the beginning, people suffered due to the absence of efficacious drugs required to treat severely ill patients. Nevertheless, still, there are no established therapeutic molecules against the SARS-CoV-2. Therefore, repurposing of the drugs starte...
Main Authors: | Chiranjib Chakraborty, Ashish Ranjan Sharma, Manojit Bhattacharya, Govindasamy Agoramoorthy, Sang-Soo Lee |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2021-11-01
|
Series: | Frontiers in Pharmacology |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fphar.2021.704205/full |
Similar Items
-
Repurposing Drugs, Ongoing Vaccine, and New Therapeutic Development Initiatives Against COVID-19
by: Rudra P. Saha, et al.
Published: (2020-08-01) -
A Database of Drug Repurposing Clinical Trials in Oncology
by: Pan Pantziarka, et al.
Published: (2021-11-01) -
Asian-Origin Approved COVID-19 Vaccines and Current Status of COVID-19 Vaccination Program in Asia: A Critical Analysis
by: Chiranjib Chakraborty, et al.
Published: (2021-06-01) -
Evolution, Mode of Transmission, and Mutational Landscape of Newly Emerging SARS-CoV-2 Variants
by: Chiranjib Chakraborty, et al.
Published: (2021-08-01) -
Therapeutic Role of Neutralizing Antibody for the Treatment against SARS-CoV-2 and Its Emerging Variants: A Clinical and Pre-Clinical Perspective
by: Manojit Bhattacharya, et al.
Published: (2022-09-01)